GEARING UP FOR A TRANSFORMATIONAL REFORM PROGRAMME
Latest News: Professor the Lord Darzi, Head of Surgery, Imperial College London, and former Health Minister, UK Government will give a keynote address at the FT China Healthcare and Life Sciences Summit. Andrew Jack, the Financial Times Pharmaceuticals and Healthcare Correspondent, will chair.
The latest programme and summit brochure are now available for download as a pdf file [download now]
As governments around the world grapple with the challenge of reforming their ailing healthcare systems, China has moved faster and further than most, launching an ambitious plan to provide universal access, transform public hospitals and create a world-beating life sciences industry, with expertise ranging from traditional Chinese medicine to innovative stem cell and gene therapy research. The resultant transformation -- if successful -- has the potential to catapult China into a leading position in healthcare innovation and advancement.
The inaugural FT China Healthcare and Life Sciences Summit will provide critical insights into this fast evolving market, its regulatory framework and financing requirements, and the steps companies from the UK and elsewhere should take to identify and meet China's changing healthcare needs, adjust their product portfolios and expand their market focus.
Themes to be covered include:
- Critical assessments of China's healthcare reform programme
- Experiences shared from the UK's state healthcare system, and lessons that can be learned from successful and unsuccessful reforms in other countries
- Capitalising on emerging opportunities in China's healthcare IT, medical devices, health insurance and medical services markets
- Seizing the opportunities in China's life sciences, assessing the implications of healthcare reform for pricing, distribution, marketing and product strategies
- Gaining a foothold in the evolving retail, wholesaling and OTC markets in China
- China as a new epicentre for life sciences innovation and investment, new frontiers in vaccines, stem cell and cutting-edge biomedical research
- Perspectives of financiers and investors on the growth potential and opportunities in China's expanding healthcare and life sciences markets
